

**Contact:**

Karen A. Donato, Ph.D.  
Vice President, Sales and Marketing  
MaxCyte, Inc.  
(301) 944-1700

**For Immediate Release**

***MaxCyte Presents a Panel Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery – LIVE Q&A to Follow***

**Gaithersburg, MD, December 15, 2008** – MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that, due to popular demand, it will be rebroadcasting its webinar with industry experts on the challenges in developing cell-based screening assays for drug discovery. The broadcast is open to the industry and will be held by webinar on Tuesday December 16<sup>th</sup> at two convenient times, 9:00 AM and 7:30 PM EST. A live Q&A will follow the broadcast.

One of the respected industry experts who led the discussion was Dr. John Reardon, formerly Senior Vice President of Discovery Research Biology at Glaxo Smith Kline and now Executive Vice President and Chief Scientific Officer at Integrated Oncology Solutions Inc. (IOS) in North Carolina. Dr. Reardon reviewed the complexities of cell transfection technologies and challenged the webinar participants to consider the possibilities of creating more relevant assays if it were possible to transfect any molecule into any cell at any scale, while maintaining biological integrity and high quality standards. His discussion offered compelling arguments as to how the MaxCyte® STX System can reduce bottlenecks and improve the productivity of drug discovery groups.

Dr James Brady, Director of Technical Applications at MaxCyte, led the webinar participants through a technical presentation of the MaxCyte® STX™ Scalable Transfection System. Dr. Brady demonstrated how the MaxCyte STX technology enables the large scale transfection of primary cells, cell lines, and stem cells with single and multiple loading agents at the same time, resulting in more relevant screening systems.

According to MaxCyte CEO Doug Doerfler, “We were delighted with the response to our previous webinar on the MaxCyte STX technology and the interest in continuing with the live panel discussion. The MaxCyte STX is being viewed by the pharmaceutical industry as an enabling technology for cell modification for both research and larger scale cell-based applications in drug discovery. The MaxCyte STX can produce billions of transfected cells in minutes compared to current time-consuming and inconsistent methods. This is possible even for large scale transfection of primary cell lines. More assays can be developed and performed in a shorter period of time, increasing the likelihood of finding a successful drug candidate.”

To register for the free webinar, visit [www.maxcyte.com](http://www.maxcyte.com) and click on the registration link. MaxCyte scientists will be available after the webinar to answer any technical questions relative to the performance and operation of the MaxCyte STX Scalable Transfection System. A recording of the webinar will be available on the MaxCyte website after the event.

## **About MaxCyte**

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. The MaxCyte transfection technology was originally developed as an enabling technology for cell therapy and is currently being used in a number of clinical trials around the world. Drawing upon this expertise in cell loading for cell therapy, MaxCyte introduced this transfection technology into drug discovery applications as the MaxCyte® STX™ Scalable Transfection System. The MaxCyte STX allows for the rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.

**For more information, [www.maxcyte.com](http://www.maxcyte.com)**

###